Skip to main content
Journal cover image

Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.

Publication ,  Journal Article
Yu, J-S; Liao, H-X; Pritchett, J; Bowman, C; Vivian, C; Parks, R; Xia, S-M; Cooper, M; Williams, WB; Bonsignori, M; Reed, SG; Chen, M ...
Published in: J Virol Methods
November 2017

Development of a HIV-1 vaccine is a major global priority. The yellow fever virus (YFV) attenuated vaccine 17D is among the most effective of currently used vaccines. However, the stability of the YFV17D vector when carrying non-flavivirus genes has been problematic. We have constructed and expressed HIV-1 Env in YFV17D with either single transmembrane (STM) or double transmembrane (DTM) YFV E protein domains for the development of anti-HIV antibodies. Here we describe modifications of the YFV17D vector such that HIV-1 Env gp120 is expressed in up to 5 passages in Vero cells. Immunization with recombinant YFV17D vector prime followed by HIV-1 CH505 TF gp120 protein boosts were able to induce neutralizing antibodies for a HIV-1 tier 1 isolate in mice. This modified YFV vector may be a starting point for constructing HIV-1 vaccine candidate priming vectors.

Duke Scholars

Published In

J Virol Methods

DOI

EISSN

1879-0984

Publication Date

November 2017

Volume

249

Start / End Page

85 / 93

Location

Netherlands

Related Subject Headings

  • Yellow fever virus
  • Virology
  • Vero Cells
  • Vaccines, DNA
  • Vaccines, Attenuated
  • Neutralization Tests
  • Mice
  • Immunization, Secondary
  • HIV-1
  • HIV Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yu, J.-S., Liao, H.-X., Pritchett, J., Bowman, C., Vivian, C., Parks, R., … Haynes, B. F. (2017). Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. J Virol Methods, 249, 85–93. https://doi.org/10.1016/j.jviromet.2017.08.012
Yu, Jae-Sung, Hua-Xin Liao, Jamie Pritchett, Cindy Bowman, Callie Vivian, Robert Parks, Shi-Mao Xia, et al. “Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.J Virol Methods 249 (November 2017): 85–93. https://doi.org/10.1016/j.jviromet.2017.08.012.
Yu J-S, Liao H-X, Pritchett J, Bowman C, Vivian C, Parks R, et al. Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. J Virol Methods. 2017 Nov;249:85–93.
Yu, Jae-Sung, et al. “Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.J Virol Methods, vol. 249, Nov. 2017, pp. 85–93. Pubmed, doi:10.1016/j.jviromet.2017.08.012.
Yu J-S, Liao H-X, Pritchett J, Bowman C, Vivian C, Parks R, Xia S-M, Cooper M, Williams WB, Bonsignori M, Reed SG, Chen M, Vandergrift N, Rice CM, Haynes BF. Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. J Virol Methods. 2017 Nov;249:85–93.
Journal cover image

Published In

J Virol Methods

DOI

EISSN

1879-0984

Publication Date

November 2017

Volume

249

Start / End Page

85 / 93

Location

Netherlands

Related Subject Headings

  • Yellow fever virus
  • Virology
  • Vero Cells
  • Vaccines, DNA
  • Vaccines, Attenuated
  • Neutralization Tests
  • Mice
  • Immunization, Secondary
  • HIV-1
  • HIV Infections